Sanofi-Aventis (SNY) Buy, Sell or Hold

Sanofi-Aventis (SNY)

42.37

-0.01 (0.02%)

as of Jun 18, 2026, 7:59:59 pm Market Open.

68 watching

BUY

A French pharma. He bought this not for its vaccine, but because it's a well-run pharma, not facing patent expirations, and has good growth and returns in the future. He doesn't know where their vaccine stands now, but if it works, it will certainly boost the stock. Has strong dividend and earnings growth.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription. It produces a drug for children aged 6-11 years with atopic dermatitis. Sales of the drug jumped almost 70% last year and it is on pace to earn the company $12 billion in revenues in the near future. The company is also vying to be another COVID-19 vaccine producer as it plans to introduce Phase 3 trials on a prospective candidate this month. It pays an excellent dividend, backed by a 38% payout ratio. We would buy SNY with a stop-loss at $45, looking towards an initial target of $61 -- 20% upside. Yield 3.36% (Analysts’ price target is $61.38)

TOP PICK

It is not economically sensitive even though the stock is getting hit. It is one of the biggest vaccine manufacturers in the world. They are working on a CoVid19 vaccine and they own an arthritis drug that could be a possible drug for treatment of CoVid19. (Analysts’ price target is $56.93)

TOP PICK

A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)

TOP PICK

A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)

PAST TOP PICK

(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.

WEAK BUY

It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.

PAST TOP PICK

(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.

HOLD

A French multi-national pharma that he owns. They get research going and buy smaller companies. They only need one or two promising drugs to make out well. A good long term hold.

HOLD

Large cap out of France. Diversified. Likes the biologic focus. Bring more of an emerging market focus. Won't shoot the lights out, but likes the stable dividend and the 7.5% EPS growth. Not paying a lot for it.

PAST TOP PICK

(A Top Pick Nov 22/17, Up 5%) They had come off a patent cliff. Now earnings are doing better. The whole US healthcare area is looking good. This one sells at a lower multiple than North American ones.

TOP PICK

The best time to buy drug stocks is after they have faced a patent cliff. They have lots of cash but they have to find new drugs by research or buy buying. Sanofi has lost competitions to buy drugs because they won’t pay too much for them. The stock has been behaving better lately as some of the acquisitions have been doing well. He thinks this is a good time to buy. (Analysts’ price target is $48.25)

TOP PICK

A French pharmaceutical company, who has been impacted by patent protection ending on some key products. They lost out on a couple of acquisitions, that the company felt was too expensive. He believes this is a long term hold that will pay off over time. Yield 4.4%. (Analysts’ price target is $46)

PAST TOP PICK

(A Top Pick May 1/17, Down 12%) He is being patient with it as they buy companies that are patient with new drugs.

COMMENT

A direct competitor of Novo-Nordisk (NVO-N) in one part of their business. Their franchise in multiple sclerosis and vaccine business is their big powerhouse, but overall, revenues only grew by 2% in the quarter, and they've seen a drop off in their diabetes cardiovascular unit, which is where the growth is. He prefers Novo-Nordisk.

Showing 16 to 30 of 43 entries

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Sanofi-Aventis (SNY)